Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MSB | Sydney | AUD | Delayed | |
MESO | NASDAQ | USD | Real-time | |
MEOBF | OTC Markets | USD | Delayed |
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Name | Age | Since | Title |
---|---|---|---|
William A. M. Burns | 72 | 2014 | Independent Non-Executive Vice Chairman |
Silviu Itescu | 64 | 2004 | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director |
Eric A. Rose | 71 | 2013 | Chief Medical Officer & Executive Director |
Henry Krum | - | - | Member of Scientific Advisory Board |
Robert M. Graham | - | - | Member of Scientific Advisory Board |
Stephen Graves | - | - | Member of Scientific Advisory Board |
Joseph M. Lane | - | - | Member of Scientific Advisory Board |
Richard E. Gilbert | - | - | Member of Scientific Advisory Board |
Philip R. Krause | - | 2022 | Non Executive Director |
Joseph Robert Swedish | 72 | 2018 | Independent Non-Executive Director |
Philip James Facchina | 62 | 2021 | Independent Non-Executive Director |
Jane Catherine Bell | - | 2022 | Independent Non-Executive Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review